Constantinos Zambirinis, MD, MRes, FSSO
@czambir.bsky.social
Surgical Oncologist & Docent at Linköping University.
🔬Studying #PancreaticCancer #Metastasis #Immunology
🔬Studying #PancreaticCancer #Metastasis #Immunology
Highlight #2 from #CCG2025
Ethical aspects of genomic data sharing, by Prof. Eva Winkler, @dkfz.bsky.social
✅ Patients willing to share data, especially with academia, but have concerns about what happens later on.
🔐Need solid data protection framework in place, and education of researchers etc.
Ethical aspects of genomic data sharing, by Prof. Eva Winkler, @dkfz.bsky.social
✅ Patients willing to share data, especially with academia, but have concerns about what happens later on.
🔐Need solid data protection framework in place, and education of researchers etc.
March 20, 2025 at 11:22 AM
Highlight #2 from #CCG2025
Ethical aspects of genomic data sharing, by Prof. Eva Winkler, @dkfz.bsky.social
✅ Patients willing to share data, especially with academia, but have concerns about what happens later on.
🔐Need solid data protection framework in place, and education of researchers etc.
Ethical aspects of genomic data sharing, by Prof. Eva Winkler, @dkfz.bsky.social
✅ Patients willing to share data, especially with academia, but have concerns about what happens later on.
🔐Need solid data protection framework in place, and education of researchers etc.
Reposted by Constantinos Zambirinis, MD, MRes, FSSO
Learn more about the APAChE study:
📄 Read the full results published in NEJM: nej.md/3IrM6T8
📄 Read the editorial by Philip J. Landrigan, MD: nej.md/48CvGSs
📺 Watch the interview with Dr. Landrigan: nej.md/41SCs6f
📄 Read the full results published in NEJM: nej.md/3IrM6T8
📄 Read the editorial by Philip J. Landrigan, MD: nej.md/48CvGSs
📺 Watch the interview with Dr. Landrigan: nej.md/41SCs6f
March 18, 2025 at 7:30 PM
Learn more about the APAChE study:
📄 Read the full results published in NEJM: nej.md/3IrM6T8
📄 Read the editorial by Philip J. Landrigan, MD: nej.md/48CvGSs
📺 Watch the interview with Dr. Landrigan: nej.md/41SCs6f
📄 Read the full results published in NEJM: nej.md/3IrM6T8
📄 Read the editorial by Philip J. Landrigan, MD: nej.md/48CvGSs
📺 Watch the interview with Dr. Landrigan: nej.md/41SCs6f
NB:
-The majority of patients were HR+ HER2-
-Only 1.2% TNBC and only 3.6% HER2+
Research summary page:
-The majority of patients were HR+ HER2-
-Only 1.2% TNBC and only 3.6% HER2+
Research summary page:
March 15, 2025 at 5:53 PM
NB:
-The majority of patients were HR+ HER2-
-Only 1.2% TNBC and only 3.6% HER2+
Research summary page:
-The majority of patients were HR+ HER2-
-Only 1.2% TNBC and only 3.6% HER2+
Research summary page:
